The sNDA filing acceptance initiates substantive FDA review for Ameluz PDT in sBCC, with a target action date of Sept. 28, 2026 and no identified filing deficiencies. Approval would establish the ...
Skin cancer is the most common type of cancer in the United States with 5.4 million new cases of the disease reported every year. TODAY contributor and New Beauty editor-at-large Sarah Eggenberger ...
Organ transplant recipients (OTRs) treated with azathioprine (AZA) face an increased risk for nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), according to an updated ...
Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...
Hosted on MSN
Pictures of What Skin Cancer Looks Like
Skin cancer is a type of cancer that begins in the skin cells, and its appearance can vary widely depending on the type of cancer. Understanding the variations in what skin cancer looks like can help ...
Researchers from the Agency for Science, Technology and Research (A*STAR) and the National Healthcare Group (NHG) have jointly pioneered an innovative imaging technique combining Multispectral ...
US FDA acknowledges no filing deficiencies in Biofrontera’s sNDA for Ameluz PDT in superficial basal cell carcinoma: Woburn, Massachusetts Saturday, February 14, 2026, 16:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results